Live
- Common Mistakes to Avoid When Hiring Executive Manufacturing Recruiters in Mexico
- Thila Taila Abhishekah Pooja to Lord Shaneswara
- Priyanka Gandhi says BJP talking of 'tinkering' with Constitution with PM’s nod
- LS polls: PM Modi says BJP-NDA leading 2-0 after first two phases
- Plea in Madras HC seeks special polling arrangement for names 'missing' from Coimbatore voter list
- Ex CM KCR Bus tour on 4 th day
- Youth National Games 2024 kick-start in Delhi; over 5,000 athletes from 15 states vying for top honours
- TN Police warn people against fraudsters using AI-based voice cloning
- L-G office blames Saurabh Bharadwaj for delay in enhancing MCD Commissioner's financial powers
- ICICI Bank posts 17 per cent rise in Q4 net profit at Rs 10,707cr; declares dividend of Rs 10 per share
Pharma cos’ top line to swell by 9% this fiscal
8-10% expansion in the domestic market and 6-8% rise in the US market supporting the domestic pharmaceutical sector’s growth: Icra
The overall credit profile of Indian pharmaceutical companies is expected to remain healthy, supported by their stable earnings profile, comfortable leverage and coverage metrics, and strong liquidity position
New Delhi: Revenue of top domestic pharmaceutical companies is likely to grow by 7-9 per cent in the current fiscal, according to rating agency Icra. The growth will be supported by an 8-10 per cent expansion in the domestic market and a 6-8 per cent rise in the US market, while revenues from the European and emerging markets are expected to increase by 3-5 per cent and 8-10 per cent, respectively, it noted. Icra said it has taken into account a sample set of 25 Indian drug firms, which constitute 60 per cent of the overall domestic industry. The segment reported a growth of 10 per cent in the 2022-23 fiscal. Icra said that a continued focus on complex generics/speciality launches in the US market is expected to support industry margins in FY2024.
The overall credit profile of Indian pharmaceutical companies is expected to remain healthy, supported by their stable earnings profile, comfortable leverage and coverage metrics, and strong liquidity position, it added. “The 8-10 per cent growth in the domestic market in FY2024 will be supported by a WPI-linked price hike of 12.1 per cent allowed for products under the National List of Essential Medicines (NLEM), new product introductions and annual price hikes for non-NLEM products,” Icra Assistant Vice President & Sector Head Mythri Macherla said. Growth in the US market is expected to moderate to 6-8 per cent in FY2024, given the large base and continued mid-high single-digit price erosion for base products, she added.
USFDA inspections have gained momentum in the recent past, and regulatory risks remain a key monitorable, the rating agency stated. The agency also pointed out the recent instances of cyber attacks on some Indian pharmaceutical companies, leading to temporary disruptions in their operations. “The frequency of such attacks and their impact on the companies’ business and financial profiles remain monitorable,” it added. The annual capex run rate for the sample set is likely to be Rs20,000 crore in FY2024. It stood at Rs51,600 crore in FY2023 due to a large acquisition by one of the companies, it added.
